Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 965 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Prefrail and Frail Young Adult Survivors of Childhood Cancers Experience Significant... July 22, 2021 Government update on the Clinical Research Vision: More needed to go... June 30, 2022 My Path to Becoming a Radiation Therapist November 12, 2020 Nirogacestat May Offer Hope to People with Desmoid Tumors May 1, 2023 Load more HOT NEWS 120 years of discovery: 10 ways we’ve changed the story for... ESMO Calls for Cancer to Be at the Core of the... Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with... Surgical Technique Helps Keep Breast Cancer Patients from Going Under the...
